Dizal to Present Latest Clinical Data at ASH 2026
· prnewswire.com · popularity 18/100 · 0 similar stories today
Read the original at prnewswire.com →
Summary
Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 10.